Arthneeti
S

Sigachi Industries Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Sigachi Industries Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹30
Market cap₹995 Cr
P/E30.6
Updated23 Aug 2026
Read4 min read

The short version

Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27. FY27 is expected to see normalization and growth with the commissioning of expanded capacities at the Dahej facility (12,000 MT capacity), targeting Q3 FY27.

From Sigachi Industries Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27.
  • Total cellulose-based excipient capacity will rise to 30,000 metric tons per annum post expansion.
  • FY27 is expected to see partial recovery in production and margins, with a more significant improvement from FY28 onwards.
  • Revenue growth of around 25% was targeted pre-incident; FY27 growth will be impacted but expected to normalize gradually.
  • The company is confident of consistent and sustainable growth over the next 2-3 years, driven by expansion in excipient capacities, API initiatives, and O&M services.
  • API revenue from Cystic Fibrosis product is expected to commercialize with INR 250 crore revenue potential after 12 months.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Sigachi Industries is undertaking a capacity expansion at the Dahej SEZ facility:
  • 12,000 metric tons per annum MCC capacity expansion expected to commission by Q3 FY27.
  • 1,800 tons CCS disintegrant facility at Dahej SEZ is also progressing, targeting the same Q3 FY27 commissioning.
  • No long-term debt currently; working capital debt only.
  • For completion of capex, company may raise equity or debt based on board decisions.
  • Capex plans also include further projects beyond Dahej, including CCS facility.
  • Exact equity/debt raise amounts are not finalized; company will announce at appropriate time.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Sigachi Industries Limited. However, some relevant points related to business outlook and demand are: - Strong customer demand continues for products, especially MCC and other excipients. - The company is focusing on capacity expansion, with Dahej facility capacity expected to ramp up fully by Q3 FY27. - There is an ongoing transition of production from Hyderabad to Dahej and Jhagadia units. - Management expressed confidence in steady and growing demand without pricing pressure.

2 more points management made on order book & pipeline

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹117 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Sigachi Indust.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Sigachi Industries Ltd Q3 FY26 results?

Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27. FY27 is expected to see normalization and growth with the commissioning of expanded capacities at the Dahej facility (12,000 MT capacity), targeting Q3 FY27.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

Sigachi Industries is undertaking a capacity expansion at the Dahej SEZ facility: - 12,000 metric tons per annum MCC capacity expansion expected to commission by Q3 FY27.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.